4DMedical (ASX:4DX) - Founder & CEO, Andreas Fouras
Founder & CEO, Andreas Fouras
Source: 4DMedical
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • 4DMedical (4DX) says its XV LVAS tech has been found to be capable of assessing regional ventilation defects in patients with chronic obstructive pulmonary disease (COPD)
  • The findings come from a clinical study involving 15 patients with a spectrum of COPD disease who received XV LVAS scans twice over the duration of the study
  • The study involved 15 patients with COPD disease who received two XV LVAS scans and other standard assessments of lung function over the duration of the study
  • 4DMedical CEO and Founder Andreas Fouras says the results show the company’s XV Technology has “significant promise” as a tool to phenotype or classify COPD disease
  • 4DX shares are down 4.64 per cent and trading at 72 cents at midday AEST

4DMedical (4DX) today announced its XV Lung Ventilation Analysis Software (XV LVAS) was found to be capable of assessing regional ventilation defects in patients with chronic obstructive pulmonary disease (COPD).

The findings come from a clinical study involving 15 patients with a spectrum of COPD disease severity who received XV LVAS scans twice over the duration of the study. The results of the study were presented at the International Conference of the American Thoracic Society in San Francisco over the weekend.

As part of the study, patients also underwent other standard assessments of lung function, including Computed Tomography (CT) scans.

The study found that 4DMedical’s XV Technology-derived metrics corresponded with COPD disease severity and measures of lung function showed reproducible results.

Further, XV LVAS scans were found to be capable of assessing regional ventilation defects. The company said this was critical to the optimisation of treatment therapies.

4DMedical CEO and Founder Andreas Fouras said the trial results meant the company’s XV Technology had “significant promise” as a tool to phenotype or classify COPD disease.

“Clinical studies like this are a key pillar of our commercialisation strategy,” Dr Fouras said.

“We are confident [the presented results] will further validate the effectiveness of our unique medical technology offering and serve to make it easier to communicate with doctors and hospitals interested in our offering.”

The company currently has a further eight clinical trials running at hospitals in the US and
Australia, including those at Cleveland Clinic, Duke, Vanderbilt and The Alfred.

4DX shares were down 4.64 per cent and trading at 72 cents at midday AEST.

4DX by the numbers
More From The Market Herald
Elsight (ASX:ELS) - CEO, Yoav Amitai

" Elsight (ASX:ELS) receives Halo order from Brazilian UAV services provider

Elsight (ASX:ELS) has received an initial order from Speedbird Aero, a leading Brazil-based comprehensive unmanned aerial…

" NRW Holdings (ASX:NWH) signs contract extension for Curragh Mine

NRW Holdings' (ASX:NWH) subsidiary, Golding Contractors, signs a $1.2 billion contract extension with Coronado Curragh, a…

" Strickland Metals (ASX:STK) uncovers new gold zones at Millrose project

Strickland Metals (ASX:STK) has announced more drill results from its Millrose gold project in Western Australia.
Investigator Resources (ASX:IVR) - Managing Director, Andrew McIlwain

" Investigator Resources (ASX:IVR) intersects high-grade silver at Uno Morgans

Investigator Resources (ASX:IVR) has intersected up to 383g/t silver from its Uno Morgans project in South…